Cited by 46Nonmelanoma Skin Cancer StudiesPhotodynamic Therapy Research StudiesSkin Protection and Aging

A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis

Reinhold, Uwe·2017·Future Oncology

Abstract

BF-200 ALA is a combination of a nanoscale-lipid vesicle formulation and the prodrug 5-aminolevulinic acid (5-ALA). The nanoemulsion stabilizes the prodrug and enhances its penetration through the stratum corneum. It has shown excellent therapeutic results in both lesion and field-directed photodynamic therapy of actinic keratosis (AK). AK is an early form of epidermal neoplasia and a precursor of invasive cutaneous squamous cell carcinoma. It is characterized by the combination of visible neoplastic lesions and surrounding tissue also harboring tumorigenic UV-induced mutations: a concept called field cancerization. A selective, field-directed treatment is ideal to meet the requirements of field change. Here, we review the clinical data on BF-200 ALA for AK along with a summary of molecular mechanisms and future perspectives.

Integrity signals

Registry

Crossref · 10.2217/fon-2017-0247

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Topical BF-200 ALA followed by red light irradiation 3 h later induced a significantly higher response rate in AK patients than PDT with 20% solution (Levulan) or 160 mg/g MAL cream (Metvixia).

    “Multiple phase III clinical trials demonstrated that topical application of BF-200 ALA followed by red light irradiation 3 h later induced a significantly higher response rate in AK patients than PDT with 20% solution (Levulan) or 160 mg/g MAL cream (Metvixia) [23].”
  • BF-200 ALA gel (Ameluz) in combination with red light was approved by the FDA in 2016 for lesion-directed and field-directed treatment of mild-to-moderate severity AK.

    “In 2016, BF-200 ALA gel (Ameluz) in combination with red light illumination (centered at ~635 nm) was approved by the FDA for lesion-directed and field-directed treatment of mild-to-moderate severity AK, making it the third ALA-based preparation approved for AK treatment and the only one approved for field-directed treatment.”

Cites

Flagged first, then by citations

1 of the 97 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Reinhold, U.
Affiliations
University Hospital Bonn (DE)
Corresponding author
Reinhold, Uwe
Venue
Future Oncology
Published
2017-08-14
Volume
13
Issue
27
Pages
2413-2428
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W2748743039
Cited by
46
References
97
Citations by year
2026: 2 · 2025: 4 · 2024: 7 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 3 · 2019: 7 · 2018: 3 · 2014: 1
FWCI
0.47
Type
journal article
Language
en
Open access
closed
Locations
  • Future Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Dermatology › Skin Protection and Aging
Keywords
5-aminolevulinic acid, photodynamic therapy, actinic keratosis, nanoemulsions, field cancerization, squamous cell carcinoma prevention, stratum corneum penetration
MeSH terms
Theranostic Nanomedicine, Aminolevulinic Acid, Emulsions, Humans, Light, Photochemotherapy, Severity of Illness Index, Treatment Outcome, Photosensitizing Agents, Clinical Trials, Phase III as Topic, Keratosis, Actinic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review